Top entities: Pacira BioSciences, Bupivacaine, Levi & Korsinsky.

What category does this event fall under?

Business — classified as class action.

What is the sentiment of coverage?

Aggregate sentiment score: -60 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

Levi & Korsinsky notifies investors Pacira BioSciences · Pacira BioSciences issued press release

Is this event still developing?

This event is archived — the story has concluded and this page is a final snapshot.

Business class action

Pacira BioSciences Patent Invalidity Lawsuit

Q: When did this event occur?

First reported Feb 07, 2025; last updated Feb 18, 2025.

Q: What is the market impact?

General. The market was significantly impacted by the invalidation of Pacira BioSciences' '495 patent for Bupivacaine, causing its stock to drop over 47% in a single day.

Analysis based on 13 articles · First reported Feb 07, 2025 · Last updated Feb 18, 2025

Sentiment

-60

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The market was significantly impacted by the invalidation of Pacira BioSciences' '495 patent for Bupivacaine, causing its stock to drop over 47% in a single day. This event raises concerns about increased generic competition and future litigation expenses for Pacira BioSciences, leading to a class action lawsuit.

Pharmaceuticals Biotechnology

Event Summary

Pacira BioSciences is facing a class action securities lawsuit initiated by Levi & Korsinsky after its stock dramatically declined by over 47% on August 9, 2024. This decline followed a court ruling that declared Pacira BioSciences' U.S. Patent No. 11,033,495 for Bupivacaine, which accounts for 80% of its revenue, as invalid in a lawsuit against eVenus. Analysts are concerned that this invalidation could lead to more generic entrants into the market and increased litigation expenses for Pacira BioSciences, affecting its future growth and profitability.

Key Actions

100 Levi & Korsinsky notifies investors Pacira BioSciences

90 Pacira BioSciences issued press release

Entities Involved

stock

Pacira BioSciences

Pacira BioSciences is the defendant in a class action lawsuit due to a significant stock price drop after its '495 patent for Bupivacaine was declared invalid, potentially leading to increased generic competition and litigation expenses.

Importance 100.0 Sentiment -70.0

oth

Bupivacaine

Bupivacaine is a product of Pacira BioSciences, whose '495 patent was declared invalid, impacting 80% of Pacira BioSciences' revenue and raising concerns about future generic competition.

Importance 80.0 Sentiment -50.0

priv

Levi & Korsinsky

Levi & Korsinsky is a law firm notifying investors of a class action securities lawsuit against Pacira BioSciences, seeking to recover losses for affected shareholders.

Importance 70.0 Sentiment 50.0

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard